AstraZeneca Bid to Expand Imfinzi’s NSCLC Label Hit with Phase III Flop

AstraZeneca’s Imfinzi (durvalumab), administered concurrently with chemoradiotherapy, missed its primary efficacy endpoint in the Phase III PACIFIC-2 trial in non-small cell lung cancer, the company announced Tuesday.